-
Procainamide Hydrochloride Research Workflows
2026-09-18
Procainamide Hydrochloride supports parallel cardiac electrophysiology, oncology, and inflammation-focused workflows rather than a single endpoint. This guide translates its sodium-channel activity and reported chemoprotective effects into practical assay designs, controls, and troubleshooting decisions.
-
Linezolid: Oxazolidinone Antimicrobial Research
2026-09-18
Linezolid is a synthetic oxazolidinone antimicrobial that inhibits bacterial protein synthesis through a 50S ribosomal mechanism. Its defined activity against MRSA, vancomycin-resistant Enterococcus, and other Gram-positive pathogens supports mechanistic, resistance, and bacterial pneumonia research.
-
NSC23766 Rac GTPase Inhibitor Workflows
2026-09-17
Build more informative Rac1 experiments with NSC23766, from dose-response and apoptosis studies to endothelial barrier and exploratory phagocytosis assays. This workflow emphasizes concentration selection, orthogonal readouts, and the distinction between Rac1-specific biology and broader cytotoxic effects.
-
Cyclic di-GMP: Biofilm and STING Workflows
2026-09-17
Cyclic di-GMP supports two complementary research directions: dissecting biofilm persistence and probing STING-driven innate immune signaling. This workflow-focused guide covers aqueous handling, assay design, cross-domain interpretation, and troubleshooting for immune modulation research, cancer immunotherapy studies, and biofilm formation regulation.
-
DAPT (GSI-IX) in Corneal Epithelial Assays
2026-09-16
DAPT (GSI-IX) gives researchers a controllable way to interrogate γ-secretase-dependent Notch and APP processing in epithelial cell systems. This workflow translates a six-component corneal culture paradigm into practical controls, dosing decisions, and troubleshooting strategies without confusing combination-medium effects with DAPT-specific biology.
-
CUDC-907: Dual PI3K/HDAC Workflow Guide
2026-09-15
CUDC-907 (SKU A4097) is a dual PI3K and HDAC inhibitor for coordinated interrogation of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis in cancer research models. This dossier-based guidance supports controlled in vitro workflows only; the compound is not intended for diagnostic, therapeutic, or clinical use.
-
KCNE4-Dependent Modulation of Kv1.3 Pharmacology
2026-09-15
The reference study shows that the leukocyte auxiliary subunit KCNE4 changes Kv1.3 blocker behavior without measurably changing blocker affinity. Its stoichiometry-dependent slowing of intracellular Psora-4 inhibition highlights why channel composition and kinetic readouts matter when interpreting Kv1.3 pharmacology in immune-cell research.
-
How Kinase Inhibitors Accelerate p38α Dephosphorylation
2026-09-14
The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also expose the activation-loop phosphothreonine to WIP1, accelerating dephosphorylation. Structural and biochemical results establish a dual-action mechanism that could guide more selective kinase-inhibitor design, while remaining preliminary for cellular and therapeutic translation.
-
iRhom2 in Olfaction and Odor-Driven Adaptation
2026-09-14
Azzopardi and colleagues identify iRhom2 as a distinctive regulator in olfactory sensory neurons and connect its expression with odor-dependent changes in olfactory receptor and activity-gene programs. The study combines mouse genetics, transcriptomics, in situ hybridization, and an ectopic receptor model to propose an iRhom2/ADAM17-linked feedback mechanism, while also defining important limits on causal interpretation.
-
Monomethyl auristatin E: A State-Aware ADC Assay
2026-09-13
Monomethyl auristatin E (MMAE) is a powerful antibody-drug conjugate payload, but potency alone does not explain response. This article connects MMAE assay design with EBV-driven cancer cell plasticity research to show how phenotype, payload delivery, and mitotic vulnerability can be measured together.
-
EGF-Driven Migration Without EMT in A549 Cells
2026-09-12
The reference study shows that EGF can stimulate A549 lung adenocarcinoma cell migration without substantially inducing epithelial–mesenchymal transition or invasion. Its comparison with TGF-β separates motility from invasive behavior and highlights MAPK-dependent, stimulus-specific mechanisms that should inform migration and metastasis assay design.
-
CHI3L1-IN-5: Astrocyte Assay Workflows
2026-09-12
CHI3L1-IN-5, also called Compound Z17, supports a dual readout strategy: suppressing CHI3L1-driven inflammation while testing astrocyte Aβ clearance and lysosomal recovery. This workflow-focused guide covers dose design, CNS-relevant interpretation, assay controls, and troubleshooting for Alzheimer’s disease and neuroinflammation research.
-
Merbromin Inhibits SARS-CoV-2 3CLpro
2026-09-11
A high-throughput enzyme screen of approximately 6,000 compounds identified Merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 3CLpro/Mpro protease. The study combines kinetic analysis, binding measurements, and molecular docking to show how this fluorescent antibacterial compound can serve as a starting point for antiviral screening and protease-inhibitor design.
-
Flumequine as a DNA Topoisomerase II Inhibitor
2026-09-11
Flumequine is a synthetic chemotherapeutic antibiotic described as a DNA topoisomerase II inhibitor with a supplier-reported IC50 of approximately 15 μM. Its defined solubility, storage, purity, and viability-assay considerations support controlled DNA replication research while limiting interpretation to the reported assay context.
-
MLN4924 HCl Salt in NAE Research
2026-09-10
MLN4924 HCl salt enables controlled interrogation of NAE-dependent protein turnover, cullin-RING ligase activity, and cell-death signaling. Its strongest use-case is a staged workflow that connects biochemical pathway inhibition with cancer biology research and virus-induced inflammation assays.